Effects of transcutaneous pulsed radiofrequency on patients with advanced cancer
- Conditions
- advanced stage cancermetastasis10027476
- Registration Number
- NL-OMON46593
- Lead Sponsor
- Radboud Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 15
1) >= 18 years of age;
2) patients with advanced-stage colorectal, breast, prostate or ovarian cancer;
3) presently no longer responding to systemic treatment, and no other standard oncological treatment can be applied anymore (i.e. a patient is strictly in a clear palliative trajectory).
4) history of tumor marker corresponding with disease progression on imaging;
5) history of tumor marker responding to previous oncological treatment;
6) patients able and willing to give written informed consent and comply with the requirement of the study protocol;
7) life expectancy at least 3 months.
1) treatment with any cancer therapy, including but not limited to chemotherapy and radiation therapy, within 4 weeks before baseline;
2) in the use of critical measuring devices, large metal implants or active implants like a pacemaker;
3) pregnant.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Tumor markers<br /><br>- Carcinoembryonic antigen (CEA) for colorectal cancer;<br /><br>- Carcinoma antigen 15.3 (CA15.3) for breast cancer;<br /><br>- Prostate-specific antigen(PSA) for prostate cancer:<br /><br>- Carcinoma antigen 125 (CA125) for ovarian Cancer.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Pain intensity will be assessed using numeric rating scale (NRS);<br /><br><br /><br>Quality of Life (QOL) will be assessed by<br /><br>-EORTC quality of life questionnaires QLQ-C30 and cancer-specific module;<br /><br>-Edmonton Symptom Assessment System (ESAS). </p><br>